Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 7/20 | 0.63 |
| ▸ | CTSL | P07711 | 6/20 | 0.63 |
| ▸ | CTSB | P07858 | 6/20 | 0.63 |
| ▸ | LIN28A | Q9H9Z2 | 2/20 | 0.60 |
| ▸ | CTSH | P09668 | 3/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | CTSD | P07339 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24186007 | 1.00 | CAPN1 (0.63) | CAPN1CTSLCTSBLIN28ACTSH | |
| SCHEMBL26727214 | 0.92 | CAPN1 (0.63) | CAPN1CTSLCTSBLIN28ACTSH | |
| SCHEMBL30668263 | 0.90 | CAPN1 (0.63) | CAPN1CTSLCTSBLIN28ACTSH | |
| SCHEMBL24186203 | 0.90 | CAPN1 (0.63) | CAPN1CTSLCTSBLIN28ACTSH | |
| SCHEMBL30668266 | 0.89 | CAPN1 (0.62) | CAPN1CTSLCTSBLIN28ACTSH | |
| SCHEMBL24186230 | 0.89 | CAPN1 (0.62) | CAPN1CTSLCTSBLIN28ACTSH | |
| SCHEMBL24186282 | 0.89 | CAPN1 (0.62) | CAPN1CTSLCTSBLIN28ACTSH | |
| SCHEMBL30668237 | 0.89 | CAPN1 (0.62) | CAPN1CTSLCTSBLIN28ACTSH | |
| SCHEMBL24186004 | 0.88 | CAPN1 (0.60) | CAPN1CTSLCTSBLIN28ACTSH | |
| SCHEMBL24186284 | 0.88 | CAPN1 (0.60) | CAPN1CTSLCTSBLIN28ACTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148716-A1 | COMPOSITIONS AND METHODS FOR ADJUVANT CANCER THERAPEUTICS | DUKE UNIVERSITY (US) | 2024-05-09 | — | — | US | disclosed |
| US-11801242-B2 | Compositions and methods for adjuvant cancer therapeutics | DUKE UNIVERSITY (US) | 2023-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11801242-B2 | Compositions and methods for adjuvant cancer therapeutics | TP53, PLK1, NRAS | CAPN1 3215/4885CTSL 1704/4885CTSB 357/4885 |
| US-20240148716-A1 | COMPOSITIONS AND METHODS FOR ADJUVANT CANCER THERAPEUTICS | TP53, PLK1, NRAS | CAPN1 3215/4885CTSL 1704/4885CTSB 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.